Colgate-Palmolive reported adjusted earnings per share of $0.95 for the fourth quarter, surpassing the consensus estimate of $0.91 by 4.4%. Quarterly net sales reached $5.23 billion, exceeding analysts’ projections of $5.118 billion. Organic sales grew in every category, led by strength in oral care and pet nutrition, excluding private label. CEO Noel Wallace highlighted double-digit growth in pet nutrition volumes and mid-single-digit organic growth in North America oral care as key drivers of outperformance.

Following the fourth-quarter release, several brokerages raised their earnings and sales forecasts for fiscal 2026. Goldman Sachs maintained its Buy rating and lifted its fiscal 2026 sales projection to a range of $20.79 billion–$21.61 billion, compared with a prior consensus of $20.98 billion. Analysts cited effective pricing strategies—up 2.7% year-over-year—and resilient volume growth in Latin America, where organic sales expanded by 6.5%. Consensus now anticipates full-year adjusted EPS growth of approximately 5% to 7%.

As a Dividend King with 63 consecutive years of annual increases, Colgate-Palmolive’s yield profile remains attractive to income-oriented investors. While the stock’s total return has historically trailed the broader market, it has outperformed the S&P 500 by an 8-to-1 margin year-to-date in 2026, driven by renewed confidence in global oral care demand and pet nutrition expansion. Management projects mid-single-digit organic sales growth for the full fiscal year, supported by innovation in premium oral care products and targeted marketing investments in emerging markets.